10 completed, 3 terminated, 2 withdrawn, 1 active not recruiting. 12 Phase 2, 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 7, Terminated 2, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 1 | 9 | Completed 6, Terminated 2, Withdrawn 1 |
Follow Aadi Bioscience, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO) nab-Sirolimus, Fulvestrant - Low Grade Ovarian Serous Adenocarcinoma | Phase 2 | Active not recruiting | University of Oklahoma | 37 | 2024-12-26 | 2026-06-12 |
| Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer nab-sirolimus - Endometrial Cancer, Endometrioid Tumor | Phase 2 | Recruiting | Aadi Bioscience, Inc. | 29 | 2023-12-28 | 2025-11-13 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors nab-sirolimus - Neuroendocrine Tumors, NET | Phase 2 | Completed | Aadi Bioscience, Inc. | 12 | 2023-10-20 | 2026-08-25 |
| Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19) Adagrasib, nab-Sirolimus - Solid Tumor, Adult, NSCLC | Phase 1 | Terminated | Mirati Therapeutics Inc. | 6 | 2023-08-07 | 2025-04-25 |
| Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment nab-sirolimus - Tumor, Solid, Tumor | Phase 1 | Completed | Aadi Bioscience, Inc. | 15 | 2022-11-23 | 2026-10-28 |
| ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome ABI-009 - Leigh Syndrome | Phase 2 | Withdrawn | Aadi Bioscience, Inc. | 2022-04-30 | 2022-02-01 | |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) nab-sirolimus - Tumor, Tumor, Solid | Phase 2 | Completed | Aadi Bioscience, Inc. | 128 | 2022-03-10 | 2026-10-28 |
| Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma ABI-009, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 1 | Withdrawn | Massachusetts General Hospital | 2019-05-30 | 2019-08-14 | |
| Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas Sirolimus Albumin-bound Nanoparticles, Pazopanib hydrochloride - Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma | Phase 1 / Phase 2 | Terminated | University of Washington | 19 | 2019-04-01 | 2025-04-30 |
| A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System ABI-009 - Neuroendocrine Tumors | Phase 2 | Terminated | Robert Ramirez | 5 | 2018-11-05 | 2021-06-10 |
| Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma nab-sirolimus, nab-sirolimus + temozolomide, nab-sirolimus + bevacizumab - High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma | Phase 2 | Completed | Aadi Bioscience, Inc. | 62 | 2018-08-01 | 2023-11-07 |
| ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE) ABI-009 - Epilepsy Intractable | Phase 1 | Completed | Seattle Children's Hospital | 14 | 2018-07-31 | 2023-05-06 |
| Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer nab-sirolimus - Colorectal Cancer Metastatic | Phase 1 / Phase 2 | Completed | Aadi Bioscience, Inc. | 60 | 2018-07-01 | 2024-01-02 |
| Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers Nab-Rapamycin, Nivolumab - Ewing Sarcoma, PEComa | Phase 1 / Phase 2 | Completed | Sarcoma Oncology Research Center, LLC | 34 | 2017-08-24 | 2025-02-17 |
| Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension nab-sirolimus - Pulmonary Hypertension | Phase 1 | Completed | Aadi Bioscience, Inc. | 15 | 2017-04-01 | 2024-11-25 |
| A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa nab-Sirolimus - Malignant PEComa | Phase 2 | Completed | Aadi Bioscience, Inc. | 34 | 2015-10-01 | 2023-04-07 |
| Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer ABI-009, Gemcitabine - Non-muscle Invasive Bladder Cancer (NMIBC) | Phase 1 / Phase 2 | Completed | Aadi Bioscience, Inc. | 21 | 2014-04-09 | 2021-06-08 |
| Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation ABI-009 - PEComa, Malignant, TSC1 | Approved for marketing | Aadi Bioscience, Inc. | 2022-03-16 |
Neoplasms (4) · Perivascular Epithelioid Cell Neoplasms (3) · Neoplasm Metastasis (2) · Neuroendocrine Tumors (2) · Sarcoma (2) · Adenoma, Islet Cell (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Chordoma (1) · Colorectal Neoplasms (1) · Desmoid Tumors (1) · Drug Resistant Epilepsy (1)
Bevacizumab (2) · Calcium Dobesilate (1) · Dexamethasone (1) · Fulvestrant (1) · Gemcitabine (1) · Lomustine (1) · Nivolumab (1) · Radiation (1) · Radiotherapy (1) · Temozolomide (1) · adagrasib (1) · marizomib (1) · pazopanib (1) · pomalidomide (1)
United States (16) · Puerto Rico (1) · South Korea (1)
Willis Navarro, MD (2) · Andrew J. Yee, MD (1) · Christina Washington, MD (1) · Erlinda M Gordon, MD (1) · James McKiernan, MD (1) · Jason Hauptman, MD, PhD (1) · Lee Cranmer, MD (1) · Leonor Nazareno (1) · Marc Simon, MD (1) · Robert Ramirez, DO (1)
PMID 24089446, PMID 31401903, PMID 34637337, PMID 38427923, PMID 41424265
R42CA171552 (1)